Last reviewed · How we verify

Merete Bechmann Christensen — Portfolio Competitive Intelligence Brief

Merete Bechmann Christensen pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Insulin Degludec 100 UNT/ML [Tresiba] Insulin Degludec 100 UNT/ML [Tresiba] marketed Long-acting basal insulin analog Insulin receptor Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Gan & Lee Pharmaceuticals. · 1 shared drug class
  2. Institut de Recherches Cliniques de Montreal · 1 shared drug class
  3. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  4. Les Laboratoires des Médicaments Stériles · 1 shared drug class
  5. Nanjing First Hospital, Nanjing Medical University · 1 shared drug class
  6. Novo Nordisk A/S · 1 shared drug class
  7. Sydney Children's Hospitals Network · 1 shared drug class
  8. The Cleveland Clinic · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Merete Bechmann Christensen:

Cite this brief

Drug Landscape (2026). Merete Bechmann Christensen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/merete-bechmann-christensen. Accessed 2026-05-14.

Related